Showing results (1-10 of 136) with videos related to

Sort By:
Pageof 14
Mediastinum (Hong Kong, China)|July 10, 2026
Systemic therapy for advanced thymic epithelial tumors: a narrative review of current evidence and perspectivesMari Tone, Takayuki Shiroyama
Immunological Medicine|May 18, 2026
Immunopathophysiology of immune checkpoint inhibitor-related pneumonitis: insights from multi-omics and immune profilingSumiyuki Nishida, Takayuki Shiroyama, Yujiro Naito, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 1, 2025
Diabetic Ketoacidosis During Lorlatinib Treatment: Case ReportAtsushi Yanagisawa, Takayuki Shiroyama, Kotaro Miyake, et al.
Respirology Case Reports|August 12, 2016
Endoscopic bronchial occlusion with silicone spigots under virtual bronchoscopic navigationManabu Hayama, Shingo Sato, Takayuki Shiroyama, et al.
Respiratory Investigation|January 22, 2023
Virtual fluoroscopic preprocedural planning using Ziostation2 for transbronchial biopsy: A prospective self-controlled studyYuko Abe, Kotaro Miyake, Takayuki Shiroyama, et al.
Lung Cancer (Amsterdam, Netherlands)|February 24, 2011
Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancerTakayuki Shiroyama, Kiyoshi Komuta, Fumio Imamura, et al.
Oncology Letters|June 25, 2014
Important factors for achieving survival of five years or more in non-small cell lung cancer patients with distant metastasisTomonori Hirashima, Hidekazu Suzuki, Norio Okamoto, et al.
BMC Palliative Care|October 15, 2014
Opioid switch from low dose of oral oxycodone to transdermal fentanyl matrix patch for patients with stable thoracic malignancy-related painSeigo Minami, Takashi Kijima, Takeshi Nakatani, et al.
Investigational New Drugs|June 17, 2020
Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective studyShingo Nasu, Hidekazu Suzuki, Takayuki Shiroyama, et al.
Investigational New Drugs|March 15, 2018
Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancerMotohiro Tamiya, Hidekazu Suzuki, Takayuki Shiroyama, et al.
Pageof 14